Physiology, Endothelial Derived Relaxation Factor (EDRF)

Article Author:
Yasaman Pirahanchi

Article Editor:
Kristen Brown

Editors In Chief:
Stephen Leslie
Karim Hamawy

Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Trevor Nezwek
Radia Jamil
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Steve Bhimji
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Nazia Sadiq
Hajira Basit
Phillip Hynes
Tehmina Warsi

1/20/2019 8:10:36 AM


Endothelium-derived relaxing factor (EDRF) is an endogenous vasodilator that endothelial cells produce and subsequently release in response to various changes in normal physiologic as well as pathophysiologic changes. EDRF causes vascular smooth muscle to relax, as it activates soluble guanylate cyclase and subsequently increases cyclic guanylate monophosphate in vascular smooth muscle. EDRF is structurally in the form of nitric oxide (NO) or a compound that contains nitrogen oxide. EDRF is formed from L-arginine by an enzyme that is dependant on calcium-calmodulin and NADPH. EDRF serves as an inhibitor of aggregation and adhesion of platelets and is a vasodilator. EDRF also serves as a second messenger for guanylyl cyclase activation and cyclic GMP production. EDRF’s function, pathophysiology, and it's clinical significance will be the subject in this review.[1]


All vascular beds, small and large vessels contain EDRF; this is true for many species. EDRF acts directly on vascular smooth muscle to invoke endogenous vasodilation and inhibiting sympathetic vasoconstriction.[2] It is the active particle in nitrovasodilating agents such as nitrates and nitroglycerin. EDRF functions as a second messenger for activation of guanylyl cyclase and the production of cyclic GMP for cells in cardiovascular tissue, respiratory and renal epithelium, macrophages, neurons of the cerebellum, and adrenocytes.[3]

EDRF serves as nitric oxide that functions through activating soluble guanylyl cyclase. Endothelial cell membranes contain an enzyme called endothelial nitric oxide synthase which produces nitric oxide, which then binds to soluble guanylyl cyclase in smooth muscle cells. This binding triggers a cell signaling cascade, ultimately leading to arteriole vasodilation. This process of endogenous nitric oxide production physiologically modulates blood flow and vasomotion.[4]

It also has antiplatelet properties by inhibiting platelet adhesion and platelet aggregation. The decrease in platelet activation directly leads to an anti-thrombotic effect.[5] NO also has anti-inflammatory properties by intrinsic inhibition of leukocytes adhesion to the endothelium.[6] It is this antithrombotic effect along with arteriole vasodilation that has had such a huge impact on the clinical arena. 


Pathophysiologic conditions affected by EDRF dysfunction include an increase in monocyte and platelet adhesion to the endothelium, myocardial infarction, atherosclerosis, and stroke. This activity may be due to increased peripheral vascular tone caused by increased superoxide radical inactivation of NO or impaired NO synthesis. For example, the first step to the atherosclerotic process is endothelial dysfunction.[7]

The quiescent endothelial cell in its normal state is attached to the endothelial cell surface and attached to the basement membrane. The endothelial cell has protective mechanisms against endothelial glycocalyx dysfunction and endothelial cell dysfunction. These protective mechanisms include a functional glycocalyx which coats the external surface of the plasma membrane in a composition of glycoprotein and glycolipid and several micro as well as macro physiologic responses to stress.

Type 1 endothelial activation, type 2 endothelial activation, endothelial apoptosis, and endothelial necrosis, all lead to endothelial dysfunction. Type 1 endothelial activation occurs almost immediately and does not require gene transcription or de novo protein synthesis. Type 2 endothelial activation can occur over a longer period, taking hours, days, or even months in some cases. In contrast to type 1 endothelial dysfunction, type 2 endothelial dysfunction requires gene transcription and de novo protein synthesis, thus requiring a longer period to progress. If endothelial activation is uncontrolled, type 2 endothelial activation can lead to endothelial apoptosis. Chronic endothelial activation can then lead to endothelial necrosis.  This is significant in cardiorenal syndrome, where endothelial dysfunction may serve as an intersection between renal dysfunction and cardiac dysfunction.[8]

Endothelial cell activation can lead to reversible endothelial dysfunction. In this case, target treatment aims to restore normal endothelial cell function and to stop the reversible endothelial dysfunction. However, if the reversible endothelial dysfunction progresses without treatment, it can lead to endothelial apoptosis and endothelial necrosis. Both endothelial apoptosis and necrosis lead to irreversible endothelial dysfunction. In this case, target treatment cannot restore normal endothelial cell function nor stop reversible endothelial dysfunction.[8]

Clinical Significance

Cardiovascular disease is among the leading causes of death today. Atherosclerosis and hypertension are major risk factors for cardiovascular disease. Endothelial dysfunction also plays a crucial role in atherosclerotic disease and hypertension. Dysfunction in EDRF can lead to an increase in platelet adhesion which subsequently increases the risk of a prothrombotic state. Dysfunction in the relaxation factor also leads to paradoxical vasoconstriction. As hypertension worsens, the increased intravascular pressures may lead to further endothelial damage. Both atherosclerotic disease and hypertension put patients at risk for more life-threatening conditions such as myocardial infarction and/or stroke.

Interventions that aim to treat endothelial dysfunction, target the underlying risk factors that cause endothelial damage. For example, medications such as ACE inhibitors and calcium channel antagonists treat hypertension, and lipid-lowering agents are used for hypercholesterolemia. Lifestyle modification also plays a large role in treatment. Smoking cessation helps to decrease the possible ramifications of cigarette smoking on endothelial dysfunction, and an increase in physical activity is used to prevent endothelial dysfunction due to a sedentary lifestyle. Chronic conditions that can lead to endothelial dysfunction can also be treated, such as increasing control of abnormal metabolic conditions in diabetes mellitus and estrogen replacement therapy in menopause. Pharmacologic agents that can achieve vascular protection in addition to their primary therapeutic indications are ACE inhibitors and HMG COA reductase inhibitors. All of these interventions help induce positive changes in the endothelium due to inhibition of vasoconstriction, promotion of vasorelaxation, decreased free radical production, or other protective mechanisms against endothelial injury.[7]

Stimulators of EDRF release include insulin and adiponectin. Chronic NO release by endothelial cells can be upregulated by dietary factors, estrogen, and exercise, and downregulated by oxidative stress, pollution, smoking, and oxidized low-density lipoproteins. NO release is also decreased with aging and in vascular diseases such as hypertension and diabetes. With impaired nitric oxide production, such as by oxidative stress, spontaneous hypertension, aging, and diabetes, this exacerbates endothelium-dependent contractions, and can contribute to decreased endothelium-dependent vasodilation in patients with essential hypertension or diabetes, as well as aging patients. Endothelin 1 can also contribute to endothelial dysfunction and vascular dysfunction. Also, under conditions of hypoxia, nitric oxide can cause unbalanced activation of soluble guanylyl cyclase such that cyclic inosine monophosphate (cIMP) production increases, instead of cGMP.  This increased cIMP can then lead to contraction of underlying vascular smooth muscle, instead of relaxation.[9]

Ischemic diseases with impaired endothelial function have impaired EDRF formation and release into the vasculature include hypercholesterolemia, atherosclerosis, hypertension-induced vascular damage, diabetes, reperfusion damage, coronary spasm, and subarachnoid hemorrhage-induced vasospasm. In these ischemic diseases, there is decreased EDRF release or hemoglobin or oxygen-derived radicals immediately inactivate the released NO before affecting the vasculature. Due to impaired EDRF release, there is an increased vasoconstrictor tone, and this is exacerbated by insufficient receptor-stimulated or mechanical NO release in large feed arteries such as coronaries. This increased vasoconstrictor tone can cause inadequate blood supply which leads to ischemic damage.[10]

Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Physiology, Endothelial Derived Relaxation Factor (EDRF) - Questions

Take a quiz of the questions on this article.

Take Quiz
Which is FALSE about endothelial-derived relaxation factor (EDRF)?

Click Your Answer Below

Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.

Sign Up
A mouse model is made where the gene responsible for making endothelium-derived relaxing factor (EDRF) is deleted. Without EDRF, what is expected to increase in this mouse model?

Click Your Answer Below

Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.

Sign Up
A morbidly obese female presents to the clinic to review lab results which are HDL 20 mg/dL, triglyceride of 230 mg/dL, cholesterol of 260 mg/dL, and LDL 300 mg/dL. She is diagnosed with hypercholesterolemia. What does the hypercholesterolemia put her at risk for on a molecular level?

Click Your Answer Below

Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.

Sign Up

Physiology, Endothelial Derived Relaxation Factor (EDRF) - References


Oliveira-Paula GH,Lacchini R,Tanus-Santos JE, Endothelial nitric oxide synthase: From biochemistry and gene structure to clinical implications of NOS3 polymorphisms. Gene. 2016 Jan 10;     [PubMed]
Paulo M,Banin TM,de Andrade FA,Bendhack LM, Enhancing vascular relaxing effects of nitric oxide-donor ruthenium complexes. Future medicinal chemistry. 2014 May;     [PubMed]
Helms CC,Gladwin MT,Kim-Shapiro DB, Erythrocytes and Vascular Function: Oxygen and Nitric Oxide. Frontiers in physiology. 2018;     [PubMed]
Gambaryan S,Tsikas D, A review and discussion of platelet nitric oxide and nitric oxide synthase: do blood platelets produce nitric oxide from L-arginine or nitrite? Amino acids. 2015 Sep;     [PubMed]
Cockrell A,Laroux FS,Jourd'heuil D,Kawachi S,Gray L,Van der Heyde H,Grisham MB, Role of inducible nitric oxide synthase in leukocyte extravasation in vivo. Biochemical and biophysical research communications. 1999 Apr 21;     [PubMed]
Zanzinger J,Czachurski J,Seller H, Inhibition of sympathetic vasoconstriction is a major principle of vasodilation by nitric oxide in vivo. Circulation research. 1994 Dec;     [PubMed]
Pesić S,Radenković M,Grbović L, [Endothelial dysfunction: mechanisms of development and therapeutic options]. Medicinski pregled. 2006 Jul-Aug;     [PubMed]
Zhang J,Bottiglieri T,McCullough PA, The Central Role of Endothelial Dysfunction in Cardiorenal Syndrome. Cardiorenal medicine. 2017 Feb;     [PubMed]
Bassenge E, Clinical relevance of endothelium-derived relaxing factor (EDRF). British journal of clinical pharmacology. 1992;     [PubMed]
Vanhoutte PM,Shimokawa H,Feletou M,Tang EH, Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta physiologica (Oxford, England). 2017 Jan;     [PubMed]


The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Surgery-Urologic. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Surgery-Urologic, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Surgery-Urologic, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Surgery-Urologic. When it is time for the Surgery-Urologic board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Surgery-Urologic.